Reached Settlement for Hikma Pharmaceuticals in Hatch-Waxman Litigation

June 14, 2022

Astellas US LLC v. Hikma Pharmaceuticals USA, Inc., 21-1785-CFC (D. Del.)

Robins Kaplan LLP reached a settlement on behalf of generic pharmaceutical manufacturer Hikma Pharmaceuticals USA, Inc., in a patent litigation arising from the Hatch-Waxman Act. Plaintiffs, who make and sell Lexiscan® (regadenoson), asserted claims for patent infringement of three patents-in-suit against Defendant, after having filed its Abbreviated New Drug Application with the FDA, seeking to make and market a generic version of regadenoson. Defendant alleged that the patents-in-suit were invalid and/or not infringed. The case settled on confidential terms.

Past results are reported to provide the reader with an indication of the type of litigation we practice. They do not and should not be construed to create an expectation of result in any other case, as all cases are dependent upon their own unique fact situation and applicable law.

Oren D. Langer


Managing Partner, New York Office

Jake M. Holdreith


Managing Partner, Minneapolis Office
Member of Executive Board

Similar Results

Back to Top